Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor. - Wikidata - wikimedia - TriplyDB

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.

http://www.wikidata.org/entity/Q46633482

about

Venetoclax for the treatment of patients with chronic lymphocytic leukemia.The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Venetoclax: First Global Approval.Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.

P2860

Q38685358-E38DE53F-8227-47F3-8E34-AEFF0098D7A0 Q38766548-FE352886-2FE7-4862-B008-9E25C61FB02E Q38853500-1C143EDB-810F-4974-AC97-86DE96752F97 Q39040977-BAAA98CF-BE4B-4375-85BB-9D20039C3AB5 Q39137457-928C0E56-BDD5-4FF0-86C6-8A4CAB742268 Q39177442-4216CB9C-78D7-4CB8-A6BA-329BCDEFDC98 Q39200835-0E7C8175-D7DA-4BDB-8636-C8992CBE4294 Q40537266-536BD837-91B7-4BD0-AF99-310C2851F758 Q40597634-63976F99-32F1-4288-A35F-EF3F024B46B1 Q45057327-C95E4ED1-3B03-4885-AAA6-38EB5B39CA65 Q47553423-AAEB188B-E178-483A-B69C-571655A7E922 Q47610956-465B3668-67B3-452B-AC59-54D30DB5A606 Q48146110-42011F7C-146D-45F9-8FA0-68CB80EB5C84 Q48257454-8F9AD76B-DD75-47E2-A12B-31DDE745995D Q50119590-E781F014-F1E6-4508-A655-5AD854A3BF1D Q51007604-59811FD6-955D-4295-95D9-E6C21E25F128 Q51280033-6A4FC1FD-39E3-469A-8D44-C58C726D97DC Q51842580-9CE23BB9-1FF0-45F8-832A-02C62D0ADE1E

P2860

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.

http://www.wikidata.org/entity/Q46633482

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Effect of Low- and High-Fat Me ...... irst-in-Class BCL-2 Inhibitor.

@en

Effect of Low- and High-Fat Me ...... irst-in-Class BCL-2 Inhibitor.

@nl

type

label

Effect of Low- and High-Fat Me ...... irst-in-Class BCL-2 Inhibitor.

@en

Effect of Low- and High-Fat Me ...... irst-in-Class BCL-2 Inhibitor.

@nl

prefLabel

Effect of Low- and High-Fat Me ...... irst-in-Class BCL-2 Inhibitor.

@en

Effect of Low- and High-Fat Me ...... irst-in-Class BCL-2 Inhibitor.

@nl

P1433

Q46633482-89C9D813-FDF0-4517-88B6-50F26CC2C932

P1476

Q46633482-487CA179-099C-43B4-9530-8E1F1C01F25A

P2093

Q46633482-3402077F-71D9-4906-BC47-724E46730B94

Q46633482-51E30C38-D8B1-414E-85C8-AB865D384739

Q46633482-740385E0-332B-44C7-9AD9-0F7463C81A5E

Q46633482-8A61C5D8-78F2-4B90-B304-6CE18689094A

Q46633482-C598407A-6CEB-438B-B620-345E453FD316

Q46633482-D4B64CE2-DAC2-4EC3-84FF-5418128CF909

P2860

Q46633482-22DA2A91-E0D8-4865-B578-CECA56EB130C

Q46633482-9EB8BBC3-CC16-4CD2-B068-CADBBF5C39A6

Q46633482-A0EE72A8-4E47-4DCA-B40A-B4C2987F6930

Q46633482-A5213E61-E09C-4BE0-94D3-1486B4894A80

Q46633482-B4805A6B-CAB7-4680-A679-EFB388DA8F3D

Q46633482-C23AC984-8FB4-4463-880E-908EF675447B

Q46633482-E1BF1373-281F-4B8F-ADC0-40217DA01CC6

Q46633482-EBCF9253-0139-40E9-B9CE-271646392403

P304

Q46633482-76DF218E-01F7-4908-8E4D-17539E2F9322

P31

Q46633482-B50D809B-0DB4-4445-B8D6-8489236EA49B

P356

Q46633482-9A9B1FFE-9CA9-459B-B091-245E60A9663C

P433

Q46633482-94095FE4-AA61-490A-9FBF-50D03F18C007

P478

Q46633482-D5B530F9-9046-4862-ADBC-B4925DBBB502

P50

Q46633482-BE0530C2-538E-4C0C-9BF6-D3A27E741919

P577

Q46633482-21ABB26D-5F7B-4E8B-B6CB-18C01208F256

P698

Q46633482-E0432168-22AE-4AA8-BD2E-85D252BC7611

P356

P1433

The Journal of Clinical Pharmacology

P1476

Effect of Low- and High-Fat Me ...... First-in-Class BCL-2 Inhibitor

@en

P2093

Ahmed Hamed Salem

http://www.w3.org/2001/XMLSchema#string

David Chien

http://www.w3.org/2001/XMLSchema#string

Kevin J Freise

http://www.w3.org/2001/XMLSchema#string

Martin Dunbar

http://www.w3.org/2001/XMLSchema#string

Shekman L Wong

http://www.w3.org/2001/XMLSchema#string

Silpa Nuthalapati

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update.

A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.

The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199.

A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.

Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.

Lymphatic Transport of Halofantrine in the Conscious Rat When Administered as Either the Free Base or the Hydrochloride Salt: Effect of Lipid Class and Lipid Vehicle Dispersion

P304

1355-1361

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.741

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Suresh K Agarwal

P577

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27029823

http://www.w3.org/2001/XMLSchema#string